LEPR and breast carcinoma: Compared to women with the LEPR Gln223Gln genotype, those harboring the heterozygous LEPR Gln223Arg genotype (OR = 1.2, 95% CI 0.8–2.0, p = 0.42) and the homozygous mutant LEPR Arg223Arg genotype (OR = 1.5, 95% CI 0.8–2.6, p = 0.16) had no significant increased risk of breast cancer.